



# DRUG UTILIZATION REVIEW BOARD MEETING AGENDA

**Date:** July 20, 2022      **Time:** 10:00am – 3:00pm (CST)      **Location:** Howerton State Office Building  
 Conference Room 202  
 Jefferson City, MO 65109

**Additional Meeting Details**

The meeting will have both in-person and virtual attendance options. Due to strict capacity limits, public attendance will be based on a first come/first serve sign-up, with a limit of **1 individual per organization**. Those unable to join in-person may listen in/provide public comment via Webex. Individuals wishing to attend in-person must contact **Carmen Burton** at [Carmen.M.Burton@dss.mo.gov](mailto:Carmen.M.Burton@dss.mo.gov) or call (573) 751-6961.

[Join Webex Meeting](#)

Meeting number (access code): 2459 080 6274  
 Meeting password: DqhpdpDF577

**Join from a Video System/Application**  
 Dial [24590806274@stateofmo.webex.com](tel:24590806274)  
 Or dial 173.243.2.68 and enter the meeting number

**Join from a Mobile Device (attendees only)**  
[1-650-479-3207](tel:16504793207) Call-in toll number (US/Canada)

[\\* Click HERE for Meeting Documents \\*](#)

**Opening Statements/Updates**

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore

**Old Business**

10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
---------------	--	------------

**New Business**

10:45 – 11:00	Proposed Actions - New Drug/Product Review (See Website and Attached Summary)	Olivia Rush
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Agents	
	iv. Prior Authorization	

**Clinical and Fiscal Edit Review**

11:00 – 1:45	Existing Criteria	Josh Moore
	i. Ampyra	
	ii. Botulinum Toxin	
	iii. Duchenne Muscular Dystrophy (DMD)	
	iv. Emsam	

- v. Gamifant
- vi. Immunoglobulin
- vii. Koselugo
- viii. Luxturna
- ix. Narcolepsy Inhibitors
- x. Neuromyelitis Optica Spectrum Disorder (NMOSD)
- xi. Nuedexta
- xii. Oxandrin
- xiii. Palforzia
- xiv. Palynziq
- xv. Ranexa
- xvi. Reblozyl
- xvii. Selective Serotonin Reuptake Inhibitors (SSRI)
- xviii. Synagis
- xix. Tepezza
- xx. Tolvaptan
- xxi. Transthyretin-Mediated Amyloidosis (ATTR)
- xxii. Xcopri
- xxiii. Zometa

New Criteria or Revision of Existing Criteria

- i. Besremi
- ii. CAR-T Cell Therapy
- iii. Crysvisa
- iv. Enjaymo
- v. Enzyme Deficiency, Select Agents
- vi. Iron, Injectable
- vii. Lambert-Eaton Myasthenic Syndrome (LEMS)
- viii. Manufacturers Requiring Prior Authorization
- ix. Psychotropic Medications Polypharmacy
- x. Parathyroid Hormone (PTH) and Bone Resorption Suppression Related Agents
- xi. Serotonin and Norepinephrine Reuptake Inhibitors (SNRI)
- xii. Targeted Immune Modulators, Small Molecule Janus Kinase (JAK) Inhibitors
- xiii. Vyvgart

**Break**

1:45 – 2:00 Lunch

**Program Utilization Information – Conduent Update**

2:00 – 2:30 Reports Jennifer Colozza

- i. Call Center Statistics
- ii. New Drug Statistics
- iii. “Top 25” Drugs by Cost/Claims

**Other Business/Closing Comments**

2:30 – 2:45 Other Business

**Executive Session**

2:45 – 3:00 Patient Profile Reviews

*Informal comments will be accepted from members of the audience at various points in the agenda.  
Times noted are approximate, agenda may move more quickly.*

**Next Meeting: October 19, 2022**

Meeting location and attendance options subject to change

MO HealthNet  
615 Howerton Ct  
2<sup>nd</sup> Floor, Conference Room 202  
Jefferson City, MO 65109  
*Public attendance may be limited*

Webex

***Motion to Close:*** *I move that this meeting be closed, and that all records and votes pertaining to and/or resulting from this closed meeting be closed, under Section 610.021 Subsection (14),(5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*